nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—type 1 diabetes mellitus	0.617	1	CbGaD
Thalidomide—Polyneuropathy—Ramipril—type 1 diabetes mellitus	0.00453	0.035	CcSEcCtD
Thalidomide—Pomalidomide—TNF—type 1 diabetes mellitus	0.00355	1	CrCbGaD
Thalidomide—Cerebral ischaemia—Ramipril—type 1 diabetes mellitus	0.00306	0.0236	CcSEcCtD
Thalidomide—Peripheral vascular disorder—Ramipril—type 1 diabetes mellitus	0.00301	0.0233	CcSEcCtD
Thalidomide—White blood cell count decreased—Ramipril—type 1 diabetes mellitus	0.00297	0.0229	CcSEcCtD
Thalidomide—Transient ischaemic attack—Ramipril—type 1 diabetes mellitus	0.00293	0.0226	CcSEcCtD
Thalidomide—NFKB1—islet of Langerhans—type 1 diabetes mellitus	0.00257	0.0945	CbGeAlD
Thalidomide—Inappropriate antidiuretic hormone secretion—Ramipril—type 1 diabetes mellitus	0.00254	0.0196	CcSEcCtD
Thalidomide—Psoriasis—Ramipril—type 1 diabetes mellitus	0.00235	0.0182	CcSEcCtD
Thalidomide—CRBN—islet of Langerhans—type 1 diabetes mellitus	0.00215	0.0792	CbGeAlD
Thalidomide—Burning sensation—Ramipril—type 1 diabetes mellitus	0.00213	0.0164	CcSEcCtD
Thalidomide—Neuralgia—Ramipril—type 1 diabetes mellitus	0.00213	0.0164	CcSEcCtD
Thalidomide—NFKB1—cardiovascular system—type 1 diabetes mellitus	0.00186	0.0684	CbGeAlD
Thalidomide—CRBN—retina—type 1 diabetes mellitus	0.00184	0.0678	CbGeAlD
Thalidomide—Myocardial ischaemia—Ramipril—type 1 diabetes mellitus	0.00184	0.0142	CcSEcCtD
Thalidomide—NFKB1—kidney—type 1 diabetes mellitus	0.00182	0.0669	CbGeAlD
Thalidomide—Endocrine disorder—Ramipril—type 1 diabetes mellitus	0.00178	0.0138	CcSEcCtD
Thalidomide—CRBN—nephron tubule—type 1 diabetes mellitus	0.00173	0.0638	CbGeAlD
Thalidomide—Proteinuria—Ramipril—type 1 diabetes mellitus	0.00168	0.013	CcSEcCtD
Thalidomide—Jaundice cholestatic—Ramipril—type 1 diabetes mellitus	0.00168	0.013	CcSEcCtD
Thalidomide—Protein urine present—Ramipril—type 1 diabetes mellitus	0.00166	0.0128	CcSEcCtD
Thalidomide—Drug interaction—Ramipril—type 1 diabetes mellitus	0.00159	0.0123	CcSEcCtD
Thalidomide—Leukocytosis—Ramipril—type 1 diabetes mellitus	0.00157	0.0121	CcSEcCtD
Thalidomide—NFKB1—lymphoid tissue—type 1 diabetes mellitus	0.00156	0.0575	CbGeAlD
Thalidomide—Creatinine increased—Ramipril—type 1 diabetes mellitus	0.00155	0.012	CcSEcCtD
Thalidomide—Hearing impaired—Ramipril—type 1 diabetes mellitus	0.00155	0.012	CcSEcCtD
Thalidomide—CRBN—pancreas—type 1 diabetes mellitus	0.00151	0.0557	CbGeAlD
Thalidomide—Hepatocellular injury—Ramipril—type 1 diabetes mellitus	0.00148	0.0114	CcSEcCtD
Thalidomide—FGFR2—cardiovascular system—type 1 diabetes mellitus	0.0014	0.0514	CbGeAlD
Thalidomide—Blood urea increased—Ramipril—type 1 diabetes mellitus	0.00139	0.0108	CcSEcCtD
Thalidomide—Neuropathy—Ramipril—type 1 diabetes mellitus	0.00139	0.0107	CcSEcCtD
Thalidomide—FGFR2—kidney—type 1 diabetes mellitus	0.00137	0.0502	CbGeAlD
Thalidomide—Rash maculo-papular—Ramipril—type 1 diabetes mellitus	0.00134	0.0104	CcSEcCtD
Thalidomide—Gynaecomastia—Ramipril—type 1 diabetes mellitus	0.00132	0.0102	CcSEcCtD
Thalidomide—Lightheadedness—Ramipril—type 1 diabetes mellitus	0.00132	0.0102	CcSEcCtD
Thalidomide—CRBN—lymphoid tissue—type 1 diabetes mellitus	0.00131	0.0482	CbGeAlD
Thalidomide—Photosensitivity—Ramipril—type 1 diabetes mellitus	0.00122	0.00943	CcSEcCtD
Thalidomide—Gastroenteritis—Ramipril—type 1 diabetes mellitus	0.00121	0.00934	CcSEcCtD
Thalidomide—Vascular purpura—Ramipril—type 1 diabetes mellitus	0.0012	0.00926	CcSEcCtD
Thalidomide—Deafness—Ramipril—type 1 diabetes mellitus	0.0012	0.00926	CcSEcCtD
Thalidomide—Renal failure acute—Ramipril—type 1 diabetes mellitus	0.00116	0.00897	CcSEcCtD
Thalidomide—Libido decreased—Ramipril—type 1 diabetes mellitus	0.00116	0.00893	CcSEcCtD
Thalidomide—Amnesia—Ramipril—type 1 diabetes mellitus	0.00114	0.00882	CcSEcCtD
Thalidomide—Dermatitis exfoliative—Ramipril—type 1 diabetes mellitus	0.00114	0.00878	CcSEcCtD
Thalidomide—Atrial fibrillation—Ramipril—type 1 diabetes mellitus	0.00113	0.00874	CcSEcCtD
Thalidomide—Purpura—Ramipril—type 1 diabetes mellitus	0.00111	0.00859	CcSEcCtD
Thalidomide—Arthritis—Ramipril—type 1 diabetes mellitus	0.0011	0.00852	CcSEcCtD
Thalidomide—Cardiac failure—Ramipril—type 1 diabetes mellitus	0.0011	0.00849	CcSEcCtD
Thalidomide—Hypoglycaemia—Ramipril—type 1 diabetes mellitus	0.0011	0.00849	CcSEcCtD
Thalidomide—Cerebrovascular accident—Ramipril—type 1 diabetes mellitus	0.00109	0.00845	CcSEcCtD
Thalidomide—Hyponatraemia—Ramipril—type 1 diabetes mellitus	0.00108	0.00832	CcSEcCtD
Thalidomide—Disturbance in sexual arousal—Ramipril—type 1 diabetes mellitus	0.00106	0.00822	CcSEcCtD
Thalidomide—Blood creatinine increased—Ramipril—type 1 diabetes mellitus	0.001	0.00776	CcSEcCtD
Thalidomide—Liver function test abnormal—Ramipril—type 1 diabetes mellitus	0.000989	0.00765	CcSEcCtD
Thalidomide—Orthostatic hypotension—Ramipril—type 1 diabetes mellitus	0.000979	0.00756	CcSEcCtD
Thalidomide—Breast disorder—Ramipril—type 1 diabetes mellitus	0.000969	0.00748	CcSEcCtD
Thalidomide—Cramp muscle—Ramipril—type 1 diabetes mellitus	0.000965	0.00746	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Ramipril—type 1 diabetes mellitus	0.000965	0.00746	CcSEcCtD
Thalidomide—Dysphagia—Ramipril—type 1 diabetes mellitus	0.000926	0.00716	CcSEcCtD
Thalidomide—Influenza—Ramipril—type 1 diabetes mellitus	0.000926	0.00716	CcSEcCtD
Thalidomide—Eosinophilia—Ramipril—type 1 diabetes mellitus	0.000917	0.00709	CcSEcCtD
Thalidomide—Bronchospasm—Ramipril—type 1 diabetes mellitus	0.000911	0.00704	CcSEcCtD
Thalidomide—Pancreatitis—Ramipril—type 1 diabetes mellitus	0.000908	0.00702	CcSEcCtD
Thalidomide—Angina pectoris—Ramipril—type 1 diabetes mellitus	0.000902	0.00697	CcSEcCtD
Thalidomide—Bronchitis—Ramipril—type 1 diabetes mellitus	0.000891	0.00688	CcSEcCtD
Thalidomide—Pancytopenia—Ramipril—type 1 diabetes mellitus	0.00088	0.0068	CcSEcCtD
Thalidomide—Neutropenia—Ramipril—type 1 diabetes mellitus	0.000866	0.00669	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Ramipril—type 1 diabetes mellitus	0.000861	0.00665	CcSEcCtD
Thalidomide—Erectile dysfunction—Ramipril—type 1 diabetes mellitus	0.000853	0.00659	CcSEcCtD
Thalidomide—Photosensitivity reaction—Ramipril—type 1 diabetes mellitus	0.000846	0.00653	CcSEcCtD
Thalidomide—Weight increased—Ramipril—type 1 diabetes mellitus	0.000843	0.00651	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Ramipril—type 1 diabetes mellitus	0.000819	0.00633	CcSEcCtD
Thalidomide—Acute coronary syndrome—Ramipril—type 1 diabetes mellitus	0.000814	0.00629	CcSEcCtD
Thalidomide—Renal failure—Ramipril—type 1 diabetes mellitus	0.000812	0.00627	CcSEcCtD
Thalidomide—Myocardial infarction—Ramipril—type 1 diabetes mellitus	0.00081	0.00626	CcSEcCtD
Thalidomide—Neuropathy peripheral—Ramipril—type 1 diabetes mellitus	0.00081	0.00626	CcSEcCtD
Thalidomide—Stomatitis—Ramipril—type 1 diabetes mellitus	0.000805	0.00622	CcSEcCtD
Thalidomide—Conjunctivitis—Ramipril—type 1 diabetes mellitus	0.000803	0.0062	CcSEcCtD
Thalidomide—Sweating—Ramipril—type 1 diabetes mellitus	0.000792	0.00612	CcSEcCtD
Thalidomide—Epistaxis—Ramipril—type 1 diabetes mellitus	0.000779	0.00602	CcSEcCtD
Thalidomide—Sinusitis—Ramipril—type 1 diabetes mellitus	0.000775	0.00599	CcSEcCtD
Thalidomide—Agranulocytosis—Ramipril—type 1 diabetes mellitus	0.000771	0.00596	CcSEcCtD
Thalidomide—Hepatitis—Ramipril—type 1 diabetes mellitus	0.000741	0.00573	CcSEcCtD
Thalidomide—Oedema peripheral—Ramipril—type 1 diabetes mellitus	0.00073	0.00564	CcSEcCtD
Thalidomide—Visual impairment—Ramipril—type 1 diabetes mellitus	0.000715	0.00552	CcSEcCtD
Thalidomide—Erythema multiforme—Ramipril—type 1 diabetes mellitus	0.000701	0.00542	CcSEcCtD
Thalidomide—Tinnitus—Ramipril—type 1 diabetes mellitus	0.000691	0.00534	CcSEcCtD
Thalidomide—CYP3A5—islet of Langerhans—type 1 diabetes mellitus	0.000683	0.0251	CbGeAlD
Thalidomide—Immune system disorder—Ramipril—type 1 diabetes mellitus	0.00067	0.00518	CcSEcCtD
Thalidomide—Mediastinal disorder—Ramipril—type 1 diabetes mellitus	0.000668	0.00516	CcSEcCtD
Thalidomide—Arrhythmia—Ramipril—type 1 diabetes mellitus	0.000662	0.00512	CcSEcCtD
Thalidomide—Alopecia—Ramipril—type 1 diabetes mellitus	0.000655	0.00506	CcSEcCtD
Thalidomide—Mental disorder—Ramipril—type 1 diabetes mellitus	0.00065	0.00502	CcSEcCtD
Thalidomide—Malnutrition—Ramipril—type 1 diabetes mellitus	0.000645	0.00499	CcSEcCtD
Thalidomide—Tension—Ramipril—type 1 diabetes mellitus	0.000633	0.00489	CcSEcCtD
Thalidomide—Dysgeusia—Ramipril—type 1 diabetes mellitus	0.000632	0.00488	CcSEcCtD
Thalidomide—Nervousness—Ramipril—type 1 diabetes mellitus	0.000627	0.00484	CcSEcCtD
Thalidomide—Muscle spasms—Ramipril—type 1 diabetes mellitus	0.000621	0.0048	CcSEcCtD
Thalidomide—Tremor—Ramipril—type 1 diabetes mellitus	0.000605	0.00467	CcSEcCtD
Thalidomide—Ill-defined disorder—Ramipril—type 1 diabetes mellitus	0.000599	0.00463	CcSEcCtD
Thalidomide—Agitation—Ramipril—type 1 diabetes mellitus	0.000593	0.00458	CcSEcCtD
Thalidomide—Angioedema—Ramipril—type 1 diabetes mellitus	0.00059	0.00456	CcSEcCtD
Thalidomide—PTGS2—islet of Langerhans—type 1 diabetes mellitus	0.000586	0.0216	CbGeAlD
Thalidomide—Malaise—Ramipril—type 1 diabetes mellitus	0.000582	0.0045	CcSEcCtD
Thalidomide—Vertigo—Ramipril—type 1 diabetes mellitus	0.00058	0.00448	CcSEcCtD
Thalidomide—Syncope—Ramipril—type 1 diabetes mellitus	0.000579	0.00447	CcSEcCtD
Thalidomide—Leukopenia—Ramipril—type 1 diabetes mellitus	0.000578	0.00446	CcSEcCtD
Thalidomide—Palpitations—Ramipril—type 1 diabetes mellitus	0.00057	0.00441	CcSEcCtD
Thalidomide—Loss of consciousness—Ramipril—type 1 diabetes mellitus	0.000567	0.00438	CcSEcCtD
Thalidomide—Cough—Ramipril—type 1 diabetes mellitus	0.000563	0.00435	CcSEcCtD
Thalidomide—Convulsion—Ramipril—type 1 diabetes mellitus	0.000559	0.00432	CcSEcCtD
Thalidomide—CYP3A5—nephron tubule—type 1 diabetes mellitus	0.00055	0.0202	CbGeAlD
Thalidomide—Myalgia—Ramipril—type 1 diabetes mellitus	0.000549	0.00425	CcSEcCtD
Thalidomide—Chest pain—Ramipril—type 1 diabetes mellitus	0.000549	0.00425	CcSEcCtD
Thalidomide—Arthralgia—Ramipril—type 1 diabetes mellitus	0.000549	0.00425	CcSEcCtD
Thalidomide—Anxiety—Ramipril—type 1 diabetes mellitus	0.000548	0.00423	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 1 diabetes mellitus	0.000546	0.00422	CcSEcCtD
Thalidomide—Discomfort—Ramipril—type 1 diabetes mellitus	0.000543	0.0042	CcSEcCtD
Thalidomide—Dry mouth—Ramipril—type 1 diabetes mellitus	0.000537	0.00415	CcSEcCtD
Thalidomide—Confusional state—Ramipril—type 1 diabetes mellitus	0.000531	0.0041	CcSEcCtD
Thalidomide—Oedema—Ramipril—type 1 diabetes mellitus	0.000527	0.00407	CcSEcCtD
Thalidomide—Shock—Ramipril—type 1 diabetes mellitus	0.000518	0.004	CcSEcCtD
Thalidomide—Nervous system disorder—Ramipril—type 1 diabetes mellitus	0.000517	0.00399	CcSEcCtD
Thalidomide—Thrombocytopenia—Ramipril—type 1 diabetes mellitus	0.000516	0.00399	CcSEcCtD
Thalidomide—Tachycardia—Ramipril—type 1 diabetes mellitus	0.000514	0.00397	CcSEcCtD
Thalidomide—CYP2E1—nephron tubule—type 1 diabetes mellitus	0.000513	0.0189	CbGeAlD
Thalidomide—Skin disorder—Ramipril—type 1 diabetes mellitus	0.000512	0.00395	CcSEcCtD
Thalidomide—Hyperhidrosis—Ramipril—type 1 diabetes mellitus	0.000509	0.00394	CcSEcCtD
Thalidomide—Anorexia—Ramipril—type 1 diabetes mellitus	0.000502	0.00388	CcSEcCtD
Thalidomide—CYP1A1—kidney—type 1 diabetes mellitus	0.000494	0.0182	CbGeAlD
Thalidomide—Hypotension—Ramipril—type 1 diabetes mellitus	0.000492	0.0038	CcSEcCtD
Thalidomide—CYP2C9—cardiovascular system—type 1 diabetes mellitus	0.000486	0.0179	CbGeAlD
Thalidomide—CYP3A5—kidney—type 1 diabetes mellitus	0.000483	0.0178	CbGeAlD
Thalidomide—Musculoskeletal discomfort—Ramipril—type 1 diabetes mellitus	0.00048	0.00371	CcSEcCtD
Thalidomide—CYP3A5—pancreas—type 1 diabetes mellitus	0.00048	0.0177	CbGeAlD
Thalidomide—Insomnia—Ramipril—type 1 diabetes mellitus	0.000476	0.00368	CcSEcCtD
Thalidomide—Paraesthesia—Ramipril—type 1 diabetes mellitus	0.000473	0.00366	CcSEcCtD
Thalidomide—Dyspnoea—Ramipril—type 1 diabetes mellitus	0.00047	0.00363	CcSEcCtD
Thalidomide—Somnolence—Ramipril—type 1 diabetes mellitus	0.000468	0.00362	CcSEcCtD
Thalidomide—Dyspepsia—Ramipril—type 1 diabetes mellitus	0.000464	0.00358	CcSEcCtD
Thalidomide—CYP2E1—cardiovascular system—type 1 diabetes mellitus	0.00046	0.0169	CbGeAlD
Thalidomide—Decreased appetite—Ramipril—type 1 diabetes mellitus	0.000458	0.00354	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ramipril—type 1 diabetes mellitus	0.000455	0.00351	CcSEcCtD
Thalidomide—Fatigue—Ramipril—type 1 diabetes mellitus	0.000454	0.00351	CcSEcCtD
Thalidomide—CYP2E1—kidney—type 1 diabetes mellitus	0.000451	0.0166	CbGeAlD
Thalidomide—Constipation—Ramipril—type 1 diabetes mellitus	0.00045	0.00348	CcSEcCtD
Thalidomide—PTGS1—cardiovascular system—type 1 diabetes mellitus	0.000444	0.0163	CbGeAlD
Thalidomide—Feeling abnormal—Ramipril—type 1 diabetes mellitus	0.000434	0.00335	CcSEcCtD
Thalidomide—PTGS1—kidney—type 1 diabetes mellitus	0.000434	0.016	CbGeAlD
Thalidomide—Gastrointestinal pain—Ramipril—type 1 diabetes mellitus	0.000431	0.00333	CcSEcCtD
Thalidomide—PTGS2—cardiovascular system—type 1 diabetes mellitus	0.000424	0.0156	CbGeAlD
Thalidomide—Urticaria—Ramipril—type 1 diabetes mellitus	0.000418	0.00323	CcSEcCtD
Thalidomide—Body temperature increased—Ramipril—type 1 diabetes mellitus	0.000416	0.00322	CcSEcCtD
Thalidomide—Abdominal pain—Ramipril—type 1 diabetes mellitus	0.000416	0.00322	CcSEcCtD
Thalidomide—PTGS2—kidney—type 1 diabetes mellitus	0.000415	0.0153	CbGeAlD
Thalidomide—PTGS2—pancreas—type 1 diabetes mellitus	0.000412	0.0152	CbGeAlD
Thalidomide—Hypersensitivity—Ramipril—type 1 diabetes mellitus	0.000388	0.003	CcSEcCtD
Thalidomide—CYP2E1—lymphoid tissue—type 1 diabetes mellitus	0.000387	0.0142	CbGeAlD
Thalidomide—Asthenia—Ramipril—type 1 diabetes mellitus	0.000378	0.00292	CcSEcCtD
Thalidomide—Pruritus—Ramipril—type 1 diabetes mellitus	0.000373	0.00288	CcSEcCtD
Thalidomide—Diarrhoea—Ramipril—type 1 diabetes mellitus	0.00036	0.00279	CcSEcCtD
Thalidomide—PTGS2—lymphoid tissue—type 1 diabetes mellitus	0.000356	0.0131	CbGeAlD
Thalidomide—Dizziness—Ramipril—type 1 diabetes mellitus	0.000348	0.00269	CcSEcCtD
Thalidomide—Vomiting—Ramipril—type 1 diabetes mellitus	0.000335	0.00259	CcSEcCtD
Thalidomide—Rash—Ramipril—type 1 diabetes mellitus	0.000332	0.00257	CcSEcCtD
Thalidomide—Dermatitis—Ramipril—type 1 diabetes mellitus	0.000332	0.00256	CcSEcCtD
Thalidomide—Headache—Ramipril—type 1 diabetes mellitus	0.00033	0.00255	CcSEcCtD
Thalidomide—Nausea—Ramipril—type 1 diabetes mellitus	0.000313	0.00242	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—TYK2—type 1 diabetes mellitus	3.15e-05	0.000142	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD86—type 1 diabetes mellitus	3.14e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HBA2—type 1 diabetes mellitus	3.13e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—G6PC2—type 1 diabetes mellitus	3.12e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—G6PC2—type 1 diabetes mellitus	3.12e-05	0.00014	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQB1—type 1 diabetes mellitus	3.1e-05	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—type 1 diabetes mellitus	3.08e-05	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—type 1 diabetes mellitus	3.05e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SH2B3—type 1 diabetes mellitus	3.04e-05	0.000137	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—type 1 diabetes mellitus	3.04e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IAPP—type 1 diabetes mellitus	3.02e-05	0.000136	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOC3—type 1 diabetes mellitus	3.02e-05	0.000136	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—type 1 diabetes mellitus	3e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD86—type 1 diabetes mellitus	2.98e-05	0.000134	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—G6PC2—type 1 diabetes mellitus	2.94e-05	0.000132	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—type 1 diabetes mellitus	2.93e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOC3—type 1 diabetes mellitus	2.93e-05	0.000132	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—type 1 diabetes mellitus	2.92e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—type 1 diabetes mellitus	2.9e-05	0.00013	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—type 1 diabetes mellitus	2.89e-05	0.00013	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—type 1 diabetes mellitus	2.89e-05	0.00013	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCC8—type 1 diabetes mellitus	2.88e-05	0.000129	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TYK2—type 1 diabetes mellitus	2.87e-05	0.000129	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—KCNJ11—type 1 diabetes mellitus	2.86e-05	0.000129	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—type 1 diabetes mellitus	2.85e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—type 1 diabetes mellitus	2.85e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB3—type 1 diabetes mellitus	2.83e-05	0.000127	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SST—type 1 diabetes mellitus	2.8e-05	0.000126	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRB1—type 1 diabetes mellitus	2.78e-05	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-B—type 1 diabetes mellitus	2.78e-05	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD86—type 1 diabetes mellitus	2.75e-05	0.000124	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2RA—type 1 diabetes mellitus	2.75e-05	0.000123	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—type 1 diabetes mellitus	2.74e-05	0.000123	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—type 1 diabetes mellitus	2.73e-05	0.000123	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-A—type 1 diabetes mellitus	2.72e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCC8—type 1 diabetes mellitus	2.71e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—type 1 diabetes mellitus	2.7e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCC8—type 1 diabetes mellitus	2.7e-05	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB3—type 1 diabetes mellitus	2.69e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOC3—type 1 diabetes mellitus	2.67e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SST—type 1 diabetes mellitus	2.65e-05	0.000119	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRB1—type 1 diabetes mellitus	2.64e-05	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—STAT3—type 1 diabetes mellitus	2.63e-05	0.000118	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2RA—type 1 diabetes mellitus	2.61e-05	0.000117	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—type 1 diabetes mellitus	2.59e-05	0.000116	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-A—type 1 diabetes mellitus	2.58e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HBA2—type 1 diabetes mellitus	2.56e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCC8—type 1 diabetes mellitus	2.55e-05	0.000115	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GCG—type 1 diabetes mellitus	2.49e-05	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB3—type 1 diabetes mellitus	2.48e-05	0.000112	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—type 1 diabetes mellitus	2.48e-05	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—type 1 diabetes mellitus	2.46e-05	0.000111	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCR5—type 1 diabetes mellitus	2.44e-05	0.00011	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ITPR3—type 1 diabetes mellitus	2.42e-05	0.000109	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—type 1 diabetes mellitus	2.41e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—G6PC2—type 1 diabetes mellitus	2.41e-05	0.000108	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC11A1—type 1 diabetes mellitus	2.4e-05	0.000108	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	2.4e-05	0.000108	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—type 1 diabetes mellitus	2.39e-05	0.000108	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HLA-A—type 1 diabetes mellitus	2.38e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GCG—type 1 diabetes mellitus	2.36e-05	0.000106	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—type 1 diabetes mellitus	2.35e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HBA2—type 1 diabetes mellitus	2.34e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VAV1—type 1 diabetes mellitus	2.33e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL10—type 1 diabetes mellitus	2.32e-05	0.000104	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—type 1 diabetes mellitus	2.3e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD80—type 1 diabetes mellitus	2.29e-05	0.000103	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ITPR3—type 1 diabetes mellitus	2.29e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—type 1 diabetes mellitus	2.28e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—type 1 diabetes mellitus	2.28e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	2.28e-05	0.000102	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HBA1—type 1 diabetes mellitus	2.27e-05	0.000102	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—KCNJ11—type 1 diabetes mellitus	2.27e-05	0.000102	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOC3—type 1 diabetes mellitus	2.26e-05	0.000102	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTT1—type 1 diabetes mellitus	2.22e-05	9.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VAV1—type 1 diabetes mellitus	2.21e-05	9.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL10—type 1 diabetes mellitus	2.2e-05	9.91e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—G6PC2—type 1 diabetes mellitus	2.2e-05	9.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD80—type 1 diabetes mellitus	2.17e-05	9.78e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOC3—type 1 diabetes mellitus	2.14e-05	9.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IAPP—type 1 diabetes mellitus	2.14e-05	9.63e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—KCNJ11—type 1 diabetes mellitus	2.14e-05	9.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—KCNJ11—type 1 diabetes mellitus	2.14e-05	9.6e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—type 1 diabetes mellitus	2.11e-05	9.51e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF2—type 1 diabetes mellitus	2.11e-05	9.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCC8—type 1 diabetes mellitus	2.09e-05	9.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—type 1 diabetes mellitus	2.07e-05	9.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—B2M—type 1 diabetes mellitus	2.06e-05	9.25e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	2.05e-05	9.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CD86—type 1 diabetes mellitus	2.03e-05	9.13e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—type 1 diabetes mellitus	2.03e-05	9.13e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—KCNJ11—type 1 diabetes mellitus	2.02e-05	9.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD80—type 1 diabetes mellitus	2.01e-05	9.03e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—STAT3—type 1 diabetes mellitus	2.01e-05	9.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—type 1 diabetes mellitus	2.01e-05	9.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF2—type 1 diabetes mellitus	2e-05	9e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HBA2—type 1 diabetes mellitus	2e-05	8.97e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TYK2—type 1 diabetes mellitus	1.93e-05	8.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.93e-05	8.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CD86—type 1 diabetes mellitus	1.93e-05	8.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—type 1 diabetes mellitus	1.93e-05	8.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ITPR3—type 1 diabetes mellitus	1.92e-05	8.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCC8—type 1 diabetes mellitus	1.9e-05	8.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—INS—type 1 diabetes mellitus	1.9e-05	8.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—G6PC2—type 1 diabetes mellitus	1.88e-05	8.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—type 1 diabetes mellitus	1.84e-05	8.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TYK2—type 1 diabetes mellitus	1.84e-05	8.25e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.83e-05	8.24e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.83e-05	8.22e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—type 1 diabetes mellitus	1.82e-05	8.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—type 1 diabetes mellitus	1.81e-05	8.15e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ITPR3—type 1 diabetes mellitus	1.81e-05	8.12e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HBA1—type 1 diabetes mellitus	1.81e-05	8.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ITPR3—type 1 diabetes mellitus	1.8e-05	8.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.8e-05	8.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOC3—type 1 diabetes mellitus	1.79e-05	8.07e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.78e-05	7.98e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GCG—type 1 diabetes mellitus	1.77e-05	7.95e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTT1—type 1 diabetes mellitus	1.76e-05	7.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—type 1 diabetes mellitus	1.75e-05	7.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.74e-05	7.81e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS1—type 1 diabetes mellitus	1.72e-05	7.75e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—type 1 diabetes mellitus	1.72e-05	7.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.71e-05	7.69e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ITPR3—type 1 diabetes mellitus	1.7e-05	7.66e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HBA1—type 1 diabetes mellitus	1.7e-05	7.64e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HBA1—type 1 diabetes mellitus	1.7e-05	7.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TYK2—type 1 diabetes mellitus	1.7e-05	7.62e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOC3—type 1 diabetes mellitus	1.69e-05	7.6e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOC3—type 1 diabetes mellitus	1.69e-05	7.58e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.68e-05	7.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—type 1 diabetes mellitus	1.66e-05	7.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—type 1 diabetes mellitus	1.66e-05	7.46e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTT1—type 1 diabetes mellitus	1.66e-05	7.46e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTT1—type 1 diabetes mellitus	1.66e-05	7.44e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—KCNJ11—type 1 diabetes mellitus	1.65e-05	7.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCC8—type 1 diabetes mellitus	1.63e-05	7.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—type 1 diabetes mellitus	1.62e-05	7.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.62e-05	7.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—type 1 diabetes mellitus	1.62e-05	7.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRKCQ—type 1 diabetes mellitus	1.61e-05	7.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—type 1 diabetes mellitus	1.61e-05	7.24e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HBA1—type 1 diabetes mellitus	1.6e-05	7.21e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOC3—type 1 diabetes mellitus	1.59e-05	7.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—VAV1—type 1 diabetes mellitus	1.57e-05	7.05e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTT1—type 1 diabetes mellitus	1.56e-05	7.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—type 1 diabetes mellitus	1.54e-05	6.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—type 1 diabetes mellitus	1.53e-05	6.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—type 1 diabetes mellitus	1.53e-05	6.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—type 1 diabetes mellitus	1.53e-05	6.87e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—KCNJ11—type 1 diabetes mellitus	1.51e-05	6.77e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAT—type 1 diabetes mellitus	1.5e-05	6.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CD80—type 1 diabetes mellitus	1.48e-05	6.66e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.44e-05	6.48e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CD80—type 1 diabetes mellitus	1.41e-05	6.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GCG—type 1 diabetes mellitus	1.4e-05	6.31e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—type 1 diabetes mellitus	1.4e-05	6.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—INS—type 1 diabetes mellitus	1.4e-05	6.3e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ITPR3—type 1 diabetes mellitus	1.39e-05	6.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD86—type 1 diabetes mellitus	1.37e-05	6.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—type 1 diabetes mellitus	1.35e-05	6.09e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.35e-05	6.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—INS—type 1 diabetes mellitus	1.33e-05	5.97e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GCG—type 1 diabetes mellitus	1.32e-05	5.94e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GCG—type 1 diabetes mellitus	1.32e-05	5.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HBA1—type 1 diabetes mellitus	1.31e-05	5.9e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOC3—type 1 diabetes mellitus	1.3e-05	5.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—KCNJ11—type 1 diabetes mellitus	1.29e-05	5.78e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—type 1 diabetes mellitus	1.29e-05	5.78e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.29e-05	5.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTT1—type 1 diabetes mellitus	1.28e-05	5.75e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ITPR3—type 1 diabetes mellitus	1.27e-05	5.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.25e-05	5.62e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GCG—type 1 diabetes mellitus	1.25e-05	5.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB3—type 1 diabetes mellitus	1.23e-05	5.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—type 1 diabetes mellitus	1.23e-05	5.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.23e-05	5.52e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—type 1 diabetes mellitus	1.21e-05	5.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HBA1—type 1 diabetes mellitus	1.2e-05	5.38e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAT—type 1 diabetes mellitus	1.19e-05	5.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOC3—type 1 diabetes mellitus	1.19e-05	5.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.19e-05	5.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—type 1 diabetes mellitus	1.19e-05	5.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—type 1 diabetes mellitus	1.18e-05	5.31e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.18e-05	5.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—type 1 diabetes mellitus	1.17e-05	5.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTT1—type 1 diabetes mellitus	1.17e-05	5.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.17e-05	5.24e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAT—type 1 diabetes mellitus	1.12e-05	5.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—type 1 diabetes mellitus	1.12e-05	5.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ITPR3—type 1 diabetes mellitus	1.09e-05	4.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—type 1 diabetes mellitus	1.08e-05	4.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.08e-05	4.84e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—type 1 diabetes mellitus	1.06e-05	4.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.04e-05	4.69e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.04e-05	4.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—type 1 diabetes mellitus	1.03e-05	4.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HBA1—type 1 diabetes mellitus	1.02e-05	4.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCG—type 1 diabetes mellitus	1.02e-05	4.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOC3—type 1 diabetes mellitus	1.02e-05	4.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—type 1 diabetes mellitus	9.97e-06	4.48e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD80—type 1 diabetes mellitus	9.97e-06	4.48e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—type 1 diabetes mellitus	9.94e-06	4.47e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—type 1 diabetes mellitus	9.89e-06	4.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—type 1 diabetes mellitus	9.88e-06	4.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—type 1 diabetes mellitus	9.46e-06	4.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—type 1 diabetes mellitus	9.42e-06	4.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCG—type 1 diabetes mellitus	9.3e-06	4.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	9.19e-06	4.13e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—type 1 diabetes mellitus	9.11e-06	4.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—type 1 diabetes mellitus	8.98e-06	4.04e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—type 1 diabetes mellitus	8.76e-06	3.94e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—type 1 diabetes mellitus	8.72e-06	3.92e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—type 1 diabetes mellitus	8.63e-06	3.88e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TYK2—type 1 diabetes mellitus	8.42e-06	3.78e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—type 1 diabetes mellitus	8.31e-06	3.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—type 1 diabetes mellitus	8.29e-06	3.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—type 1 diabetes mellitus	8.26e-06	3.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—type 1 diabetes mellitus	7.96e-06	3.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCG—type 1 diabetes mellitus	7.95e-06	3.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—type 1 diabetes mellitus	7.89e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—type 1 diabetes mellitus	7.87e-06	3.54e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—type 1 diabetes mellitus	7.61e-06	3.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—type 1 diabetes mellitus	7.55e-06	3.4e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—type 1 diabetes mellitus	7.43e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—type 1 diabetes mellitus	7.41e-06	3.33e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—type 1 diabetes mellitus	7.23e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—type 1 diabetes mellitus	7e-06	3.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—type 1 diabetes mellitus	6.92e-06	3.11e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—type 1 diabetes mellitus	6.81e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—type 1 diabetes mellitus	6.8e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—type 1 diabetes mellitus	6.73e-06	3.02e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—type 1 diabetes mellitus	6.51e-06	2.93e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—type 1 diabetes mellitus	6.5e-06	2.92e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—type 1 diabetes mellitus	6.42e-06	2.89e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—type 1 diabetes mellitus	6.14e-06	2.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—type 1 diabetes mellitus	6.12e-06	2.75e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—type 1 diabetes mellitus	5.89e-06	2.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—type 1 diabetes mellitus	5.81e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—type 1 diabetes mellitus	5.73e-06	2.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—type 1 diabetes mellitus	5.36e-06	2.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—type 1 diabetes mellitus	5.25e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—type 1 diabetes mellitus	5.23e-06	2.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—type 1 diabetes mellitus	5.03e-06	2.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—type 1 diabetes mellitus	4.79e-06	2.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—type 1 diabetes mellitus	4.58e-06	2.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—type 1 diabetes mellitus	4.47e-06	2.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—type 1 diabetes mellitus	4.12e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—type 1 diabetes mellitus	4.09e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—type 1 diabetes mellitus	3.92e-06	1.76e-05	CbGpPWpGaD
